Events

Loading Events

« All Events

  • This event has passed.

2021 SLP Model-Informed Drug Development Conference

March 3 - March 4

Thank you to the thousands of pharmaceutical scientists who registered for the inaugural MIDD+ scientific conference.

Our goal was to design an optimized & inspiring experience for modeling & simulation scientists and students. Offering six high-quality MIDD-focused tracks representing the drug development journey, expert modelers from Cognigen, DILIsym Services, Lixoft, Simulations Plus, and more presented novel M&S technologies to promote public health and safety through innovative scientific and in silico solutions. Watch presentation replays below!

 

Main Stage


Discovery


Pre-Clinical


FIH/Phase I


Phase II


Phase III


Post-Approval/Generics


 

 

Outstanding Woman in Science Award

Intended to recognize exceptional and outstanding achievement by a distinguished female scientist in the area of modeling and simulation

Winner: Julie Stone
Distinguished Scientist, Quantitative Pharmacology and Pharmacometrics, Merck

 

Excellence in Academia Award

Intended to recognize the outstanding contributions of an academic scientist, whose research and publications serve to support the development of innovative quantitative solutions that optimize treatment options for patients

Winner: Stephan Schmidt
Director, Center for Pharmacometrics and Systems Pharmacology at University of Florida

 

STEM Forward Award

Intended to promote and elevate the contributions and leadership activities of a researcher from an under-represented population working in the pharmaceutical industry, academia, or in a governmental agency or other non-profit organization

Winner: Aruna Dontabhaktuni
Founder & Scientific Director, Project Dontabhaktuni | Founder & CEO, PharmaPro Consulting

 

View open positions now!

 

In Case You Missed A Recent Webinar or Product Video:

GastroPlus® v9.8.1 DDI Standards Update and Documentation Project

IPFsym™, a platform to support the development of effective treatments for IPF patients